I think a brief look back may hold the reasons for the shortfall.
Everyone is always quoting DYOR.
So, would you invest in a company that did their last SPP @ .28cents for Ph11b and Ph3 testing in 5/2011 and are now going to the mkt and asking for more funds to do ancillary testing using the same process on different cancer types with a SP @.08cents.
Does anything else need be said.
DYOR
the spp shortfall, page-3
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.3¢ | 36.5¢ | $1.060M | 2.841M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48648 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 13814 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |